Cardiovoyage LLC

1. Akebia Therapeutics Inc $271,234 143 payments
2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $188,152 27 payments
3. Novartis Pharmaceuticals Corporation $183,840 12 payments
4. AstraZeneca Pharmaceuticals LP $116,072 8 payments
5. Inari Medical, Inc. $28,192 20 payments
6. Retrophin, Inc. $27,593 22 payments
7. H. Lundbeck A S $23,669 15 payments
8. Amgen Inc. $22,620 3 payments
9. Harmony Biosciences LLC $18,019 6 payments

1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $109,923 6 payments
2. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $90,893 12 payments
3. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $63,058 10 payments
4. Akb-6548-Ci-0014 $56,821 65 payments
5. The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $47,637 2 payments
6. The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $45,225 4 payments
7. Akb-6548-Ci-0015 $43,344 51 payments
8. Bmad $38,134 6 payments
9. A Randomized, Controlled, Multicenter, Open-Label Trial Comparing A Post-Discharge Care Pathway Involving Aggressive LDL-C Management With Inclisiran With Usual Care in Patients With A Recent Acute Coronary Syndrome $36,373 1 payment
10. Maps $35,540 3 payments

1. Other $26,239 20 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.